window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 14, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

PulseSight Therapeutics

  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Therapeutic Areas

    PulseSight completes Phase 1 dosing of gene therapy candidate PST-611 in dry AMD and geographic atrophy

    PulseSight Therapeutics has completed dosing in its Phase 1 clinical [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • PharmaForceIQ launches AI platform for pharma commercial teams
    Categories: Biotech & Pharma Business, Digital & Data
  • Biogen’s felzartamab approved in China for multiple myeloma
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics
  • Agenus reports deep responses with immunotherapy in Phase 2 colon cancer study
    Categories: Advanced Therapies, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top